The initiation of efficacy studies on a patented technology in collaboration with reputable partners is a positive development for Mangoceuticals. The fact that the studies are pre-funded and do not require additional capital reduces financial risk. The expected completion by early Q3 2024 provides a clear timeline for potential results, which could drive investor interest and positively impact the stock price in the short term.